drugset
drugset / Trial / NCT04270370

A Study of LY3478045 in Healthy Participants

NCT04270370 ↗

Phase 1 Completed 72 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study in healthy participants is to learn more about the safety of LY3478045 and any side effects that might be associated with it. The study will also measure how much LY3478045 gets into the bloodstream and how long it takes the body to get rid of it. This study has two parts: Part A (one dose) will last about six weeks and Part B (more than one dose) will last about eight weeks for each participant.

Timeline

Start
2020-03-16
Primary completion
2021-06-23
Completion
2021-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg Oral
Subject LY3478045 Unknown 20 mg Oral
Subject LY3478045 Unknown 60 mg Oral
Subject LY3478045 Unknown 160 mg Oral
Subject LY3478045 Unknown 180 mg Oral
Subject LY3478045 Unknown 300 mg Oral
Subject LY3478045 Unknown 360 mg Oral
Subject LY3478045 Unknown 500 mg Oral
Subject LY3478045 Unknown 700 mg Oral

Indications

No indication recorded.